schliessen

Filtern

 

Bibliotheken

Selection Criteria for Drug-Eluting Versus Bare-Metal Stents and the Impact of Routine Angiographic Follow-Up: 2-Year Insights From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial

OBJECTIVES: We sought to identify patients with ST-segment elevation myocardial infarction most likely to benefit from drug-eluting stents (DES), and to evaluate the impact of routine angiographic follow-up on the apparent differences between stent types. BACKGROUND: DES might have greatest utility... Full description

Journal Title: Journal of the American College of Cardiology Nov 2, 2010, Vol.56(19), pp.1597-1604
Main Author: Stone, Gregg
Other Authors: Parise, Helen , Witzenbichler, Bernhard , Kirtane, Ajay , Guagliumi, Giulio , Peruga, Jan , Brodie, Bruce , Dudek, Dariusz , Moeckel, Martin , Lansky, Alexandra , Mehran, Roxana
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0735-1097
Link: http://search.proquest.com/docview/954579496/?pq-origsite=primo
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: proquest954579496
title: Selection Criteria for Drug-Eluting Versus Bare-Metal Stents and the Impact of Routine Angiographic Follow-Up: 2-Year Insights From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
format: Article
creator:
  • Stone, Gregg
  • Parise, Helen
  • Witzenbichler, Bernhard
  • Kirtane, Ajay
  • Guagliumi, Giulio
  • Peruga, Jan
  • Brodie, Bruce
  • Dudek, Dariusz
  • Moeckel, Martin
  • Lansky, Alexandra
  • Mehran, Roxana
subjects:
  • Implants
  • Clinical Trials
  • 24310
ispartof: Journal of the American College of Cardiology, Nov 2, 2010, Vol.56(19), pp.1597-1604
description: OBJECTIVES: We sought to identify patients with ST-segment elevation myocardial infarction most likely to benefit from drug-eluting stents (DES), and to evaluate the impact of routine angiographic follow-up on the apparent differences between stent types. BACKGROUND: DES might have greatest utility in patients who would benefit most from their antirestenotic properties. METHODS: We randomly assigned 3,006 patients with ST-segment elevation myocardial infarction to paclitaxel-eluting stents (PES) or to bare-metal stents (BMS). Events were assessed at 12 months and 24 months, with a subset undergoing routine angiographic follow-up at 13 months. Using well-known risk factors for restenosis and target lesion revascularization (TLR), risk groups were formed to examine the absolute differences between PES and BMS. RESULTS: Compared with BMS, PES reduced TLR at 12 months from 7.4% to 4.5% (p = 0.003). Insulin-treated diabetes mellitus (hazard ratio: 3.12), reference vessel diameter ,3.0 mm (hazard ratio: 2.89), and lesion length .30 mm (hazard ratio: 2.49) were independent predictors of 12-month TLR after BMS. In patients with 2 or 3 of these baseline risk factors, PES compared with BMS markedly reduced 12-month TLR (19.8% vs. 8.1%, p = 0.003). In patients with 1 of these risk factors, the 12-month rates of TLR were modestly reduced by PES (7.3% vs. 4.3%, p = 0.02). The 12-month TLR rates were low and similar for both stents in patients with 0 risk factors (3.3% vs. 3.2%, p = 0.93). Routine 13-month angiographic follow-up resulted in a marked increase in TLR procedures (more so with BMS) so that the absolute incremental benefit of PES compared with BMS doubled from 2.9% at 12 months to 6.0% at 24 months, a difference evident in all risk strata. CONCLUSIONS: Patients at high risk for TLR after BMS in ST-segment elevation myocardial infarction for whom DES are of greatest benefit may be identified. Conversely, DES may be of less clinical benefit for patients at lower risk for TLR after BMS. Routine angiographic follow-up increases the perceived clinical benefits of DES, and must be avoided to accurately estimate absolute treatment effects. (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI]; NCT00433966)
language: eng
source:
identifier: ISSN: 0735-1097
fulltext: fulltext
issn:
  • 07351097
  • 0735-1097
url: Link


@attributes
ID1586212972
RANK0.06999999
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid954579496
sourceidproquest
recordidTN_proquest954579496
sourcesystemPC
pqid954579496
galeid240521849
display
typearticle
titleSelection Criteria for Drug-Eluting Versus Bare-Metal Stents and the Impact of Routine Angiographic Follow-Up: 2-Year Insights From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
creatorStone, Gregg ; Parise, Helen ; Witzenbichler, Bernhard ; Kirtane, Ajay ; Guagliumi, Giulio ; Peruga, Jan ; Brodie, Bruce ; Dudek, Dariusz ; Moeckel, Martin ; Lansky, Alexandra ; Mehran, Roxana
contributorLansky, Alexandra (correspondence author)
ispartofJournal of the American College of Cardiology, Nov 2, 2010, Vol.56(19), pp.1597-1604
identifierISSN: 0735-1097
subjectImplants ; Clinical Trials ; 24310
descriptionOBJECTIVES: We sought to identify patients with ST-segment elevation myocardial infarction most likely to benefit from drug-eluting stents (DES), and to evaluate the impact of routine angiographic follow-up on the apparent differences between stent types. BACKGROUND: DES might have greatest utility in patients who would benefit most from their antirestenotic properties. METHODS: We randomly assigned 3,006 patients with ST-segment elevation myocardial infarction to paclitaxel-eluting stents (PES) or to bare-metal stents (BMS). Events were assessed at 12 months and 24 months, with a subset undergoing routine angiographic follow-up at 13 months. Using well-known risk factors for restenosis and target lesion revascularization (TLR), risk groups were formed to examine the absolute differences between PES and BMS. RESULTS: Compared with BMS, PES reduced TLR at 12 months from 7.4% to 4.5% (p = 0.003). Insulin-treated diabetes mellitus (hazard ratio: 3.12), reference vessel diameter ,3.0 mm (hazard ratio: 2.89), and lesion length .30 mm (hazard ratio: 2.49) were independent predictors of 12-month TLR after BMS. In patients with 2 or 3 of these baseline risk factors, PES compared with BMS markedly reduced 12-month TLR (19.8% vs. 8.1%, p = 0.003). In patients with 1 of these risk factors, the 12-month rates of TLR were modestly reduced by PES (7.3% vs. 4.3%, p = 0.02). The 12-month TLR rates were low and similar for both stents in patients with 0 risk factors (3.3% vs. 3.2%, p = 0.93). Routine 13-month angiographic follow-up resulted in a marked increase in TLR procedures (more so with BMS) so that the absolute incremental benefit of PES compared with BMS doubled from 2.9% at 12 months to 6.0% at 24 months, a difference evident in all risk strata. CONCLUSIONS: Patients at high risk for TLR after BMS in ST-segment elevation myocardial infarction for whom DES are of greatest benefit may be identified. Conversely, DES may be of less clinical benefit for patients at lower risk for TLR after BMS. Routine angiographic follow-up increases the perceived clinical benefits of DES, and must be avoided to accurately estimate absolute treatment effects. (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI]; NCT00433966)
languageeng
source
version10
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttp://search.proquest.com/docview/954579496/?pq-origsite=primo$$EView_record_in_ProQuest_(subscribers_only)
search
creatorcontrib
0Stone, Gregg
1Parise, Helen
2Witzenbichler, Bernhard
3Kirtane, Ajay
4Guagliumi, Giulio
5Peruga, Jan
6Brodie, Bruce
7Dudek, Dariusz
8Moeckel, Martin
9Lansky, Alexandra
10Mehran, Roxana
titleSelection Criteria for Drug-Eluting Versus Bare-Metal Stents and the Impact of Routine Angiographic Follow-Up: 2-Year Insights From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
descriptionOBJECTIVES: We sought to identify patients with ST-segment elevation myocardial infarction most likely to benefit from drug-eluting stents (DES), and to evaluate the impact of routine angiographic follow-up on the apparent differences between stent types. BACKGROUND: DES might have greatest utility in patients who would benefit most from their antirestenotic properties. METHODS: We randomly assigned 3,006 patients with ST-segment elevation myocardial infarction to paclitaxel-eluting stents (PES) or to bare-metal stents (BMS). Events were assessed at 12 months and 24 months, with a subset undergoing routine angiographic follow-up at 13 months. Using well-known risk factors for restenosis and target lesion revascularization (TLR), risk groups were formed to examine the absolute differences between PES and BMS. RESULTS: Compared with BMS, PES reduced TLR at 12 months from 7.4% to 4.5% (p = 0.003). Insulin-treated diabetes mellitus (hazard ratio: 3.12), reference vessel diameter ,3.0 mm (hazard ratio: 2.89), and lesion length .30 mm (hazard ratio: 2.49) were independent predictors of 12-month TLR after BMS. In patients with 2 or 3 of these baseline risk factors, PES compared with BMS markedly reduced 12-month TLR (19.8% vs. 8.1%, p = 0.003). In patients with 1 of these risk factors, the 12-month rates of TLR were modestly reduced by PES (7.3% vs. 4.3%, p = 0.02). The 12-month TLR rates were low and similar for both stents in patients with 0 risk factors (3.3% vs. 3.2%, p = 0.93). Routine 13-month angiographic follow-up resulted in a marked increase in TLR procedures (more so with BMS) so that the absolute incremental benefit of PES compared with BMS doubled from 2.9% at 12 months to 6.0% at 24 months, a difference evident in all risk strata. CONCLUSIONS: Patients at high risk for TLR after BMS in ST-segment elevation myocardial infarction for whom DES are of greatest benefit may be identified. Conversely, DES may be of less clinical benefit for patients at lower risk for TLR after BMS. Routine angiographic follow-up increases the perceived clinical benefits of DES, and must be avoided to accurately estimate absolute treatment effects. (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI]; NCT00433966)
subject
0Implants
1Clinical Trials
224310
3X
general
0English
1ProQuest Biological Science Collection
2ProQuest Environmental Science Collection
3ProQuest Natural Science Collection
4ProQuest SciTech Collection
5Agricultural & Environmental Science Database
6Biological Science Database
7Natural Science Collection
8SciTech Premium Collection
sourceidproquest
recordidproquest954579496
issn
007351097
10735-1097
rsrctypearticle
creationdate2010
addtitleJournal of the American College of Cardiology
searchscope
01007488
11007944
210000004
310000006
410000038
510000043
610000050
710000120
810000198
910000200
1010000209
1110000217
1210000234
1310000238
1410000253
1510000260
16proquest
scope
01007488
11007944
210000004
310000006
410000038
510000043
610000050
710000120
810000198
910000200
1010000209
1110000217
1210000234
1310000238
1410000253
1510000260
16proquest
lsr43
01007488false
11007944false
210000004false
310000006false
410000038false
510000043false
610000050false
710000120false
810000198false
910000200false
1010000209false
1110000217false
1210000234false
1310000238false
1410000253false
1510000260false
contributorLansky, Alexandra
startdate20101102
enddate20101102
citationpf 1597 pt 1604 vol 56 issue 19
lsr30VSR-Enriched:[pqid, doi, galeid, eissn]
sort
titleSelection Criteria for Drug-Eluting Versus Bare-Metal Stents and the Impact of Routine Angiographic Follow-Up: 2-Year Insights From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
authorStone, Gregg ; Parise, Helen ; Witzenbichler, Bernhard ; Kirtane, Ajay ; Guagliumi, Giulio ; Peruga, Jan ; Brodie, Bruce ; Dudek, Dariusz ; Moeckel, Martin ; Lansky, Alexandra ; Mehran, Roxana
creationdate20101102
lso0120101102
facets
frbrgroupid1147399357049156775
frbrtype5
languageeng
creationdate2010
topic
0Implants
1Clinical Trials
224310
collection
0ProQuest Biological Science Collection
1ProQuest Environmental Science Collection
2ProQuest Natural Science Collection
3ProQuest SciTech Collection
4Agricultural & Environmental Science Database
5Biological Science Database
6Natural Science Collection
7SciTech Premium Collection
prefilterarticles
rsrctypearticles
creatorcontrib
0Stone, Gregg
1Parise, Helen
2Witzenbichler, Bernhard
3Kirtane, Ajay
4Guagliumi, Giulio
5Peruga, Jan
6Brodie, Bruce
7Dudek, Dariusz
8Moeckel, Martin
9Lansky, Alexandra
10Mehran, Roxana
jtitleJournal of the American College of Cardiology
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Stone
1Parise
2Witzenbichler
3Kirtane
4Guagliumi
5Peruga
6Brodie
7Dudek
8Moeckel
9Lansky
10Mehran
aufirst
0Gregg
1Helen
2Bernhard
3Ajay
4Giulio
5Jan
6Bruce
7Dariusz
8Martin
9Alexandra
10Roxana
au
0Stone, Gregg
1Parise, Helen
2Witzenbichler, Bernhard
3Kirtane, Ajay
4Guagliumi, Giulio
5Peruga, Jan
6Brodie, Bruce
7Dudek, Dariusz
8Moeckel, Martin
9Lansky, Alexandra
10Mehran, Roxana
addauLansky, Alexandra
atitleSelection Criteria for Drug-Eluting Versus Bare-Metal Stents and the Impact of Routine Angiographic Follow-Up: 2-Year Insights From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
jtitleJournal of the American College of Cardiology
risdate20101102
volume56
issue19
spage1597
epage1604
pages1597-1604
issn0735-1097
formatjournal
genrearticle
ristypeJOUR
abstractOBJECTIVES: We sought to identify patients with ST-segment elevation myocardial infarction most likely to benefit from drug-eluting stents (DES), and to evaluate the impact of routine angiographic follow-up on the apparent differences between stent types. BACKGROUND: DES might have greatest utility in patients who would benefit most from their antirestenotic properties. METHODS: We randomly assigned 3,006 patients with ST-segment elevation myocardial infarction to paclitaxel-eluting stents (PES) or to bare-metal stents (BMS). Events were assessed at 12 months and 24 months, with a subset undergoing routine angiographic follow-up at 13 months. Using well-known risk factors for restenosis and target lesion revascularization (TLR), risk groups were formed to examine the absolute differences between PES and BMS. RESULTS: Compared with BMS, PES reduced TLR at 12 months from 7.4% to 4.5% (p = 0.003). Insulin-treated diabetes mellitus (hazard ratio: 3.12), reference vessel diameter ,3.0 mm (hazard ratio: 2.89), and lesion length .30 mm (hazard ratio: 2.49) were independent predictors of 12-month TLR after BMS. In patients with 2 or 3 of these baseline risk factors, PES compared with BMS markedly reduced 12-month TLR (19.8% vs. 8.1%, p = 0.003). In patients with 1 of these risk factors, the 12-month rates of TLR were modestly reduced by PES (7.3% vs. 4.3%, p = 0.02). The 12-month TLR rates were low and similar for both stents in patients with 0 risk factors (3.3% vs. 3.2%, p = 0.93). Routine 13-month angiographic follow-up resulted in a marked increase in TLR procedures (more so with BMS) so that the absolute incremental benefit of PES compared with BMS doubled from 2.9% at 12 months to 6.0% at 24 months, a difference evident in all risk strata. CONCLUSIONS: Patients at high risk for TLR after BMS in ST-segment elevation myocardial infarction for whom DES are of greatest benefit may be identified. Conversely, DES may be of less clinical benefit for patients at lower risk for TLR after BMS. Routine angiographic follow-up increases the perceived clinical benefits of DES, and must be avoided to accurately estimate absolute treatment effects. (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI]; NCT00433966)
urlhttp://search.proquest.com/docview/954579496/
doi10.1016/j.jacc.2010.08.608
eissn15583597
date2010-11-02